Acumen and JCR partner on brain delivery therapy for Alzheimer’s
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery…
Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery…
Illimis Therapeutics has completed a Series B funding round, securing $42m to expedite the development of its Gas6-mediated Anti-Inflammatory Adaptor…
Niagen Bioscience has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital, Bergen, Norway, for the development of…
The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid…
Novartis has completed its previously announced acquisition of US-based biopharmaceutical company Regulus Therapeutics for $1.7bn, strengthening its renal disease portfolio.…
In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for…
Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies…
Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals.…
The US Food and Drug Administration (FDA) has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat…
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to…